Iterum Therapeutics (ITRM)

[Vector93]

Relypsa was projected to bring in peak annual sales of $1B and got bought out 9 months after FDA approval for $1.5 Billion.

Their competitor ZS-9 had similar projections and was bought for $2.7 Billion even before FDA approval.

The current PPS and market cap of ITRM is a gift for anyone willing to buy and hold for the next 6 months to a year.